PRNewsWire
01 Jun 2026, 09:28 UTC · 4h ago
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
Search tags
PRNewsWire
01 Jun 2026, 09:28 UTC · 4h ago
Search tags
Story key points
3 claims · impact-rated
Gossamer Bio's Phase 3 PROSERA study for seralutinib failed to meet its primary endpoint for treating pulmonary arterial hypertension. — The failure of a Phase 3 trial for a potential first-in-class therapeutic eliminates a major growth catalyst and direct revenue path.
-1.00Gossamer Bio is currently not meeting the $1 minimum bid price required for continued listing on the Nasdaq Global Select Market. — Potential delisting increases volatility and liquidity risk, often triggering further sell-offs from institutional investors.
-0.70A securities class action lawsuit has been filed against Gossamer Bio alleging the company misled investors regarding the PROSERA trial design and patient recruitment. — Legal proceedings create additional financial liabilities and reputational damage, further depressing investor confidence.
-0.50Ticker attribution
Continue reading
6 related stories
Model heads
The company faces a securities class action lawsuit following a failed Phase 3 clinical trial and an 80% drop in stock price.
Merck is mentioned only as a reference for a successful study in a different trial.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
6h ago
